arrow
N

Nigel S. Key

University of North Carolina at Chapel Hill
H指数:83
被引数:2.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Durability of efficacy, safety, and quality of life 5 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A: final phase 3 GENEr8-1 trial results

重度A型血友病患者接受valoctocogene roxaparvovec基因转移后5年的疗效、安全性和生活质量持久性:GENEr8-1 III期试验最终结果

2026-04-010
OAAI
Rapid Detection of Fibrinolytic Activation in Postpartum Hemorrhage and Acute Obstetric Coagulopathy Using a Novel Assay

使用一种新型检测方法对产后出血及急性产科凝血功能障碍中的纤溶激活进行快速检测

2025-12-310
OAAI
Natural history of preexisting AAV5 antibodies in adults with hemophilia B during the lead-in of the etranacogene dezaparvovec phase 3 study

在etranacogene dezaparvovec III期研究的导入期中,成年B型血友病患者中预先存在的AAV5抗体的自然史

2025-08-180
OAAI
Anticoagulation for the Prevention of Thrombotic Events in Nephrotic Syndrome [Kidney International Reports (vol 9, pg 3053, 2024)

《抗凝治疗预防肾病综合征中的血栓事件》 [Kidney International Reports (vol 9, pg 3053, 2024)]

2025-01-010
OAAI
Addressing the pathophysiology of venous thrombosis and chronic kidney disease in sickle cell trait using a mouse model

利用小鼠模型探讨镰状细胞特质中静脉血栓形成和慢性肾脏疾病的病理生理机制

2025-01-010
OA
Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr8-1 trial

在3期GENEr8-1试验中,valoctocogenene roxaparvovec基因转移治疗严重血友病A后4年的疗效,安全性和生活质量

2024-11-010
OAAI